Sigma-Tau Pharmaceuticals, Inc. is a research-based pharmaceutical company
focused on the discovery of molecules and therapies to help improve the lives
of people who suffer from rare diseases.
This product information is intended for U.S. residents only. You should
not construe anything on this site as a promotion or solicitation for any
product or for the use of any product outside the United States.
| Development Program |
|
Indication |
|
Development Stage |
|
| Cystaran® (cysteamine hydrochloride ophthalmic solution) 0.44% |
|
Treatment of corneal cystine crystal accumulation in patients with Cystinosis |
|
Under FDA Review |
| Defibrotide in severe Venous Occlusive Disease |
|
Treatment of Hepatic venous occlusive disease after stem cell transplantation |
|
Under FDA Review |
| EZN-2279 (Polyethylene Glycol Recombinant Adenosine Deaminase [PEG-rADA]) |
|
For enzyme replacement therapy for adenosine deaminase (ADA) deficiency in patients with severe combined immunodeficiency disease (SCID) who are not suitable candidates for or who have failed bone marrow transplantation. |
|
Phase III |
| EZN-2285 (calaspargase pegol) |
|
Treatment of Acute Lymphoblastic Leukemia (ALL) |
|
Phase III |
| Nuartez™ (artesunate) Injection in severe
malaria |
|
Immediate treatment of severe and complicated falciparum
malaria |
|
NDA/Preparation |
| orBec® (oral beclomethasone dipropionate) |
|
Treatment of acute Graft versus-Host disease |
|
Phase III |
| STP-206 live biotherapeutic |
|
Prevention of necrotizing enterocolitis (NEC) |
|
Phase I |
| Xenbilox® (chenodeoxycholic acid) Capsules |
|
Treatment of cerebrotendinous xanthomatosis (CTX) |
|
NDA/Preparation |
|
